What is Halozyme Therapeutics?
Halozyme Therapeutics is a drug delivery technology company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Drug delivery technology
- Headquarters
- San Diego, CA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: HALO
What is Halozyme Therapeutics?
Halozyme Therapeutics is a drug delivery technology company headquartered in San Diego, CA.
Halozyme Therapeutics operates in drug delivery technology and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around ENHANZE, Subcutaneous drug delivery, Partner royalties, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Halozyme Therapeutics is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: HALO, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Halozyme Therapeutics offer?
Halozyme Therapeutics's profile centers on ENHANZE, Subcutaneous drug delivery, Partner royalties, Auto-injector assets.
- ENHANZE· Drug delivery technology
- Subcutaneous drug delivery· Drug delivery technology
- Partner royalties· Drug delivery technology
- Auto-injector assets· Drug delivery technology
- Oncology partner products· Drug delivery technology
- Biologics delivery· Drug delivery technology
How does Halozyme Therapeutics make money?
Halozyme Therapeutics makes money through commercial activity tied to drug delivery technology.
Halozyme Therapeutics monetizes through the commercial model common to drug delivery technology: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Halozyme Therapeutics?
Halozyme Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Halozyme Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Halozyme Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Halozyme Therapeutics technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Halozyme Therapeutics's leadership?
Halozyme Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.halozyme.com- Halozyme Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.halozyme.com
- Halozyme Therapeutics sales or partnershipsCommercial contact routecontact via https://www.halozyme.com
- Halozyme Therapeutics media relationsMedia or communications contact routecontact via https://www.halozyme.com
How is Halozyme Therapeutics funded?
Halozyme Therapeutics's current status is Public company; Nasdaq: HALO.
Halozyme Therapeutics's current capital profile is best understood through its current status: Public company; Nasdaq: HALO. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Halozyme Therapeutics get here?
Halozyme Therapeutics's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingHalozyme Therapeutics is foundedThe company begins building in drug delivery technology.
- Scale-upCommercial footprint expandsHalozyme Therapeutics broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: HALOOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Halozyme Therapeutics's competitors?
Halozyme Therapeutics competes with larger platform incumbents and focused specialists in drug delivery technology.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Halozyme Therapeutics — frequently asked questions
